After a 22% year-to-date decline in early April, the XBI biotech index staged a remarkable recovery to end 2025 up 37%. This turnaround was fueled by a robust M&A environment, with over $15 billion in deals, including major acquisitions by J&J, Novartis, and Merck, marking the best year for deal-making since 2019.
The obesity market remained a central focus, propelling Eli Lilly to become the first healthcare company with a $1 trillion valuation. Competition intensified with Pfizer and Novo Nordisk engaging in a bidding war for MetSara, and the next frontier is emerging with oral GLP-1 drugs, with Lilly's expected to be approved in Q1 2026.
The U.S. FDA was described as being in a state of 'chaos and dysfunction' due to leadership turnover, creating regulatory uncertainty. Simultaneously, the Trump administration's efforts on drug pricing and cuts to research funding at agencies like the NIH pose long-term risks to the innovation ecosystem.
2025 was marked by significant company-specific events, from major setbacks to strategic successes. Sarepta Therapeutics faced a crisis with multiple patient deaths and failed confirmatory trials, while Third Harmonic Bio was praised for the mature decision to shut down and return capital to shareholders.
Moderna is at a critical juncture, navigating the post-COVID cliff and political headwinds against mRNA technology. The company's future heavily relies on its pipeline, particularly the mRNA cancer vaccine being co-developed with Merck, with the first Phase 3 data expected in late 2026.
Keep pulling the thread on Adam Feuerstein.